Utah committee adopts second-sub HB203 to expand oversight, add ombudsman and limited new pharmacy licenses

Representative Veil Provost, sponsor of HB203, told the Natural Resources and Environment Committee that the bill is aimed at strengthening Utah—s medical cannabis program, not creating a recreational market. "This bill does not create a cannabis program. It doesn't eliminate a cannabis program and it doesn't actually expand—excuse me, expand or change the fact that we have medical cannabis pharmacies in the state of Utah," she said as she opened the presentation.

The bill, discussed at length on multiple committee panels and in public comment, would create a medical cannabis ombudsman within the Department of Health and Human Services, clarify rulemaking and enforcement roles between DHHS and the Department of Agriculture and Food, and raise the statutory cap on pharmacy licenses from 15 to 20. The measure also creates a phased plan that would make two new pharmacy licenses available in the next two years but limits those early licenses to applicants who do not already own other cannabis license types; the change is intended to encourage independent pharmacies and improve access in underserved rural counties.

Why it matters: Sponsors argued the changes respond to patient access challenges, high costs and limited geographic coverage because the existing capped-license, vertically integrated market leaves some Utah communities with no nearby medical cannabis pharmacy. Provost told the committee that patients leaving the regulated medical program often obtain products out of state or from unregulated sources. "We're trying to incentivize patients coming into and staying in the medical program under the care of their providers," she said.

Regulatory oversight and transparency were central to the debate. The substitute creates an ombudsman office to provide an independent avenue for licensees to raise concerns about agency enforcement and rulemaking and to participate in certain licensing recommendations. Several committee members and public commenters criticized the proposed ombudsman as too powerful or insufficiently limited; opposing commenters warned the office could delay rulemaking or tilt regulatory authority away from existing boards. Danny Bordeaux of Preservation of Family Values said the ombudsman "is given way too much power" and flagged a list of procedural authorities he said were unconstrained by the bill.

Supporters, including patient-advocacy and industry representatives, said the ombudsman would add transparency rather than take power away from agencies. Desiree Hennessy of the Utah Patients Coalition called the addition "another layer of oversight and accountability" that patients and licensees can use. Nareth, representing Dragonfly Wellness, cited an internal analysis showing reduced opioid use among medical cannabis patients in rural Price after local pharmacy access improved, and urged the committee to approve the bill.

Several health-care providers and community members warned that cannabis products can pose risks to adolescents and should not be treated like recreational products. Opponents also raised concerns about advertising and the potential for the program to resemble recreational markets in neighboring states. Sponsor Provost repeatedly emphasized statutory limits on potency remain unchanged and said the bill keeps the regulated medical program distinct from recreational systems.

Votes and next steps: The committee adopted the second substitute on a voice vote, then voted 8—5 to advance the second sub with a favorable recommendation to the full House. Representative Chiu moved adoption of the second substitute; Representative Watkins moved passage of the second substitute with the favorable recommendation. The roll call for the final committee vote was recorded in the transcript and showed eight members in favor and five opposed. With the committee recommendation, the bill moves to the House floor for additional consideration.

Context: The committee heard more than a dozen public speakers during a split public-comment period; speakers included industry operators, patients, physicians and advocacy groups on both sides of the proposal. Sponsors and regulators said they will continue stakeholder work in interim and that aspects of the program (including advertising rules and working groups) will be subject to further refinement.

Ending: Proponents said the measure is an incremental, stakeholder-driven effort to increase access in underserved areas and add accountability to enforcement; opponents said it expands market activity and raises public-safety and youth-exposure concerns. The bill now goes to the House floor with a favorable committee recommendation and the adopted second substitute.